CCG-232964

• Description:

  CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF. CCG-232964 inhibits LPA-induced CTGF gene expression[1].

• UNSPSC:

  12352005

• Target:

  Ras; ROCK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Cytoskeleton; GPCR/G Protein; MAPK/ERK Pathway; Stem Cell/Wnt; TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/ccg-232964.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C (O) CCCSC1=NN=C (C2=CC=C (C3CC3) C=C2Cl) O1

• Molecular Formula:

  C15H15ClN2O3S

• Molecular Weight:

  338.81

• References & Citations:

  [1]Kahl, Dylan, et al. 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF) /Serum Reponse Factor (SRF) -Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. Journal of Medicinal Chemistry, (), acs.jmedchem.8b01772–.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2349373-70-0